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GENERAL COMMENTS
The paper presented is quite interesting. Despite that there are some issues that need to be addressed.
First of all, the threshold used for polypharmacy is not adequate. Despite the authors reported a couple of references stating 9 drugs as a threshold, several papers about polypharmacy in various clinical setting, established 5 drugs as a threshold for polypharmacy. I would like to suggest to the authors to add an analysis using 5 drugs as a threshold and then consider 9 drugs as a further threshold as "severe polypharmacy".
Second, the authors stated some assumptions to justify the collected sample size, but they don't provide any source for these data. Please amend.
In the first paragraph of Results, the authors stated some analyses, despite not showing those results. Maybe they would like to add those data as supplementary materials.
One of the main limitation of the study is the low number of subjects enrolled. Despite stating this clearly in the Limitations section, they do not state this issue in the Abstract. Indeed, the authors should mitigate the Conclusions section in the abstract.
VERSION 1 -AUTHOR RESPONSE
Reviewer:
Although there is a reference, the authors might consider to explain a bit more detailed why furosemide is a marker for congestive heart failure. Is this due to the indication? In Europe, this drug is licensed for various indications.
Response:
The patient-chart documentation of congestive heart failure was often erratic and appeared to be incomplete/inaccurate. However, given the possible confounding of CHF as a cause of lower blood pressure (independent to or intentionally related to specific pharmacotherapy choices) The authors felt that being able to have some other indicator of CHF would be more useful. One of our authors (JM) was an author on the paper cited as rationale for choice of furosemide (Lancet 1998; 352: 943-48 ) and suggested doing the same for this paper. As per your suggestion, I have done some review to ensure that this assumption is reasonable (i.e. furosemide is a fair estimate for presence of a diagnosis of CHF) and have found the following that supports this decision. Tables 3 and 4 ) has been added for both hypertension and diabetes, comparing those over treated to those not and showing frequency of the drugs prescribed. This was not included originally, given the small sample size, but as you note, the data may be interesting to other people doing this kind of study on a larger scale.
4) In the discussion section, the authors may consider to mention that a more "aggressive" drug regime might also be due to concomitant drug prescriptions with blood glucose raising effects.
Response: Thank you for this suggestion. The study team reviewed it while we agree that some drugs, e.g. statins and thiazides are known to cause increase in serum glucose, and in doing so, they might initiate a prescribing cascade that would add another drug on to dealing with the "high" sugar, we observed the opposite. Despite the tendency of other medications to raise glucose, we are still finding that lower sugars are associated with greater use of non-glucose lowering medication.
Response: Thank you for this comment. The definition of what constitutes polypharmacy is indeed arbitrary. We have found that accurate descriptions of what is counted and how are actually quite sparse and processes used, as well as "cut points" seem to be incredibly varied. For this sample, only 12.6% were prescribed <=4 medications, as they were counted in this study. Upon review of the data and the other studies done in Canada, the study team decided that Bronskill's (PMID: 21839687) (and many others PMID: 25869992) use of 9 would be best suited to our intention to present information about treatment intensity of hypertension and diabetes.
